Drug Discovery

Synaffix, ABL Bio partner to develop bispecific ADCs

Lonza company Synaffix has signed a licensing agreement with ABL Bio for the development of bispecific antibody drug conjugates (ADCs).

Salipro and Sumitomo Pharma sign partnership for drug discovery programme

Salipro Biotech and Sumitomo Pharma have entered into a research partnership for advancing a drug discovery programme.

United Italian Trading launches GERD drug in Singapore

RaQualia Pharma’s sublicensee United Italian Trading (UITC) has launched the tegoprazan drug for the treatment of gastroesophageal reflux disease (GERD), in Singapore.

Innovac raises funding for lead programmes development

Innovac Therapeutics has raised $18m in Series Pre-A financing for funding the development of its lead programmes and manufacturing capabilities.

Allucent to expedite Covid-19 booster vaccines development

Allucent has received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to expedite clinical research and development of next-generation booster vaccines for Covid-19.

Daiichi Sankyo to close Japanese research and development subsidiary

Daiichi Sankyo has announced its decision to shut down its Japanese research and development (R&D) subsidiary to further strengthen its capabilities.

Solu Therapeutics raises funds to develop CyTaC platform and drug candidates

Precision-medicine company Solu Therapeutics has raised $31m in seed financing to develop the Cytotoxicity Targeting Chimera (CyTaC) platform and drug candidates.

Viatris, Kindeva launch Breyna to treat asthma and COPD patients

Viatris and Kindeva Drug Delivery have launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol to treat certain asthma and chronic obstructive pulmonary disease (COPD) patients.

NMPA accepts Overland ADCT BioPharma’s BLA for ZYNLONTA

The China National Medical Products Administration (NMPA) has accepted and granted priority review to Overland ADCT BioPharma’s biologics license application (BLA) for ZYNLONTA (loncastuximab tesirine-lpyl).